These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 20400271)

  • 1. Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
    An MM; Zou Z; Shen H; Gao PH; Cao YB; Jiang YY
    Int J Antimicrob Agents; 2010 Jul; 36(1):58-65. PubMed ID: 20400271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
    Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxifloxacin monotherapy versus ß-lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia.
    Ewig S; Hecker H; Suttorp N; Marre R; Welte T;
    J Infect; 2011 Mar; 62(3):218-25. PubMed ID: 21276814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials.
    Yuan X; Liang BB; Wang R; Liu YN; Sun CG; Cai Y; Yu XH; Bai N; Zhao TM; Cui JC; Chen LA
    J Chemother; 2012 Oct; 24(5):257-67. PubMed ID: 23182045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxifloxacin monotherapy for treatment of complicated intra-abdominal infections: a meta-analysis of randomised controlled trials.
    Mu YP; Liu RL; Wang LQ; Deng X; Zhu N; Wei MD; Wang Y
    Int J Clin Pract; 2012 Feb; 66(2):210-7. PubMed ID: 22257046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.
    Katz E; Larsen LS; Fogarty CM; Hamed K; Song J; Choudhri S
    J Emerg Med; 2004 Nov; 27(4):395-405. PubMed ID: 15498622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment.
    Wenisch C; Krause R; Széll M; Laferl H
    Infection; 2006 Aug; 34(4):190-5. PubMed ID: 16896576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials.
    Falagas ME; Matthaiou DK; Bliziotis IA
    J Antimicrob Chemother; 2006 Apr; 57(4):639-47. PubMed ID: 16501057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
    Solomkin J; Zhao YP; Ma EL; Chen MJ; Hampel B;
    Int J Antimicrob Agents; 2009 Nov; 34(5):439-45. PubMed ID: 19692210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia.
    Tessmer A; Welte T; Martus P; Schnoor M; Marre R; Suttorp N
    J Antimicrob Chemother; 2009 May; 63(5):1025-33. PubMed ID: 19293196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials.
    Bliziotis IA; Samonis G; Vardakas KZ; Chrysanthopoulou S; Falagas ME
    Clin Infect Dis; 2005 Jul; 41(2):149-58. PubMed ID: 15983909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis: randomized controlled trials of clindamycin/aminoglycoside vs. beta-lactam monotherapy for the treatment of intra-abdominal infections.
    Falagas ME; Matthaiou DK; Karveli EA; Peppas G
    Aliment Pharmacol Ther; 2007 Mar; 25(5):537-56. PubMed ID: 17305755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
    Segreti J; House HR; Siegel RE
    Am J Med; 2005 Jul; 118 Suppl 7A():21S-28S. PubMed ID: 15993674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
    Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia.
    Ambroggio L; Taylor JA; Tabb LP; Newschaffer CJ; Evans AA; Shah SS
    J Pediatr; 2012 Dec; 161(6):1097-103. PubMed ID: 22901738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
    Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
    Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis: ertapenem for complicated intra-abdominal infections.
    Falagas ME; Peppas G; Makris GC; Karageorgopoulos DE; Matthaiou DK
    Aliment Pharmacol Ther; 2008 May; 27(10):919-31. PubMed ID: 18266994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis.
    Ott SR; Hauptmeier BM; Ernen C; Lepper PM; Nüesch E; Pletz MW; Hecht J; Welte T; Bauer TT
    Eur Respir J; 2012 Mar; 39(3):611-8. PubMed ID: 21965229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.